Citations

Showing 10 of 108152 citations.

PERSISTENT MEDIASTINAL POSITRON EMISSION TOMOGRAPHY (PET)‐POSITIVITY AFTER FRONTLINE THERAPY FOR HODGKIN LYMPHOMA IS BEST MANAGED BY CLOSE OBSERVATION
Nowakowski, G. S., Micallef, I.N., Johnston, Patrick B. , Inwards, David J. , Ristow, Kay M., Ansell, Stephen M. , Novo, Mattia , Habermann, Thomas M. , Witzig, Thomas E. , Young, Jason R.

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 48-49

10.1002/hon.18_2629 Get It

IBRUTINIB FOR THE TREATMENT OF BING‐NEEL SYNDROME: A RETROSPECTIVE, MULTICENTER STUDY
Buske, Christian , Eyre, Toby A. , Shain, Kenneth H. , Palomba, Lia, Simpson, David , Tedeschi, Alessandra , Ansell, Stephen M. , Nayak, Lakshmi , Castillo, Jorge J. , Itchaki, Gilad , Paludo, Jonas , Varettoni, Marzia , Chavez, Julio C , Issa, Samar , Pasvolsky, Oren , Talaulikar, Dipti , Tam, Constantine S. , Treon, Steven P.

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 183-184

10.1002/hon.140_2629 Get It

ACALABRUTINIB PLUS PEMBROLIZUMAB IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: A PHASE 1/2 STUDY
Witzig, T.E. , Maddocks, Kami J. , Vos, Sven de , Lyons, Roger M. , Edenfield, WJ, Sharman, Jeff P. , Yimer, Habte, Chan, Emily , Patel, Pankaj , Simone, Christopher Di, Gandhi, M., Vaughn, Jennifer E. , Cheson, Bruce D. , Samaniego, Felipe , Vose, Julie M. , Wei, Helen , Patel, P., Vaughn, J., Kolibaba, Kathryn S.

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 327-328

10.1002/hon.139_2630 Get It

A FIRST‐IN‐HUMAN TRIAL OF THE NOVEL MULTI‐ACTION THERAPY TINOSTAMUSTINE (EDO‐S101) IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) HODGKIN LYMPHOMA (HL)
Pinto, A., Hilgier, Kasia, Remmy, D., Mehrling, Thomas , O’Connor, Owen A. , Filippi, Rosaria De , Zinzani, Pier Luigi , Driessen, Christoph , Tun, Han W.

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 326-326

10.1002/hon.137_2630 Get It

INVESTIGATING SAFETY AND PRELIMINARY EFFICACY OF AFM13 PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE
Ansell, Stephen M. , Chen, R.W., Herrera, Alex F. , Forero‐Torres, Andres , Armand, Philippe , Devata, Sumana, Izquierdo, Antonia Rodríguez, Lossos, Izidore S. , Reeder, Craig B. , Sher, Taimur , Choe-Juliak, Cassandra, Prier, Kim, Schwarz, Sylvia E., Strassz, András, Alland, Leila, Bartlett, Nancy L. , Domingo‐Doménech, Eva , Mehta, Amitkumar , García‐Sánz, Ramón

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 177-178

10.1002/hon.134_2629 Get It

REDUCED BCL2 EXPRESSION SUGGESTS ALTERNATIVE SURVIVAL MECHANISMS IN HIV(+) DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) OF GERMINAL CENTER ORIGIN
Maguire, Alanna , Chen, X., Wisner, Lee, Malasi, Smriti, Ramsower, Colleen , Barrett, Michael T. , Glinsmann‐Gibson, Betty, McGrath, Michael S. , Kendrick, Samantha , Rimsza, Lisa M.

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 198-198

10.1002/hon.12_2630 Get It

THE HIGH COST OF CANCER DRUGS: WHAT CAN WE DO?
Rajkumar, S. Vincent

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 172-172

10.1002/hon.129_2629 Get It

NIVOLUMAB PLUS DOXORUBICIN, VINBLASTINE AND DACARBAZINE FOR NEWLY DIAGNOSED ADVANCED‐STAGE CLASSICAL HODGKIN LYMPHOMA: CHECKMATE 205 COHORT D 2‐YEAR FOLLOW‐UP
Ansell, Stephen M. , Ramchandren, Radhakrishnan , Rueda, A. , Feldman, Tatyana , Lee, H., Sillaber, C., Cohen, Jonathon B. , Willenbacher, Wolfgang , Sumbul, Anne, Armand, Philippe , Domingo‐Doménech, Eva , Trněný, Marek , Savage, Kerry J. , Sacchi, M.

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S2 | Pages: 146-147

10.1002/hon.104_2629 Get It

Multiple myeloma: Every year a new standard?
Rajkumar, S. Vincent

Mayo Clinic

Hematological Oncology | June 12, 2019 | Volume: 37 | Issue: S1 | Pages: 62-65

10.1002/hon.2586 | PMID 31187526 Get It

AbstractThe treatment of myeloma is rapidly evolving. This article reviews the current diagnostic criteria, risk stratification, and approach to treatment of multiple myeloma. Treatment approach for both newly diagnosed and relapsed disease are discussed.